




















![]()
Q1: 2026-05-07 Earnings Summary
EPS of -$0.84 misses by $0.22
|
Revenue of
$194.52M
(66.78% Y/Y)
beats by $15.90M
BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDT
Company Participants
Chinmay Shukla - Senior Vice President of Strategic Finance
Neil Kumar - Co-Founder, CEO & Director
Matthew Outten - Chief Commercial Officer
Thomas Trimarchi - CFO & President
Anna Wade - BD & Operations
Conference Call Participants
Samuel Rollenhagen - TD Cowen, Research Division
Mani Foroohar - Leerink Partners LLC, Research Division
Biren Amin - Piper Sandler & Co., Research Division
Cory Kasimov - Evercore ISI Institutional Equities, Research Division
Salim Syed - Mizuho Securities USA LLC, Research Division
Eliana Merle - Barclays Bank PLC, Research Division
Anupam Rama - JPMorgan Chase & Co, Research Division
Derek Archila - Wells Fargo Securities, LLC, Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Lin Tsai - Jefferies LLC, Research Division
Danielle Brill Bongero - Truist Securities, Inc., Research Division
Jason Zemansky - BofA Securities, Research Division
John Boyle - William Blair & Company L.L.C., Research Division
Presentation
Operator
Good afternoon. I will be your conference operator today. [Operator Instructions]
Before we begin, I would like to remind everyone that today's call may contain forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements about BridgeBio's future operating and financial performance, business plans and prospects and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward-looking statements.
For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release in BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law.
With that completed, BridgeBio, you may
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。